1. Generics Bulletin
  2. >>Leadership
  3. >>Interviews

Pharmascience Looks Back At First Year Of New CDMO Unit

Pharmascience’s John Foy Discusses The Company’s Latest Efforts And Plans

 
• By Adam Zamecnik

Almost a year since the establishment of an expanded CDMO business unit, Canada’s Pharmascience has doubled down on its plans to expand its presence through the pharmaceutical industry.

Pin of Canadian flag on a map
(Shutterstock)

Since the changing of its CEO at the start of 2023, the Canadian generics manufacturer Pharmascience has pushed onwards in its efforts to grow its presence in the pharmaceutical industry.

In a September 2023 exclusive interview with Generics Bulletin, Pharmascience’s then recently appointed CEO Martin Arès

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Interviews

More from Generics Bulletin

Celltrion Reinforces Commitment To UK Biosimilars Market With New HQ

 
• By Dave Wallace

Celltrion has reinforced its commitment to the UK by opening a new central operations hub in Uxbridge, while acknowledging that “major questions over the attractiveness of the market” need to be addressed to encourage development and ensure a sustainable environment for UK biosimilars.

‘Prices Can Remain Contaminated Indefinitely’: Advanz Brushed Aside On UK Liothyronine Appeal

 
• By Dean Rudge

England’s Court of Appeal has upheld a Competition Appeal Tribunal’s 2023 finding that Advanz and its former owner Cinven abused their dominant position in the UK market for liothyronine tablets by charging prices that were many orders of magnitude higher than the benchmark for fair pricing.

Tevogen Will House Generics Unit In Much-Expanded New Headquarters

 
• By Dean Rudge

Tevogen is looking to accelerate its growth with a major expansion of its headquarters in Warren, New Jersey, more than doubling its footprint to centralize research and development, regulatory, and corporate functions. The new facility will support the company’s evolving initiatives.